A Prednisone Dose Right at the Threshold: Perioperative Steroid Coverage or Not
A single patient whose steroid dose sits precisely on the line two published frameworks define oppositely, tested against major joint replacement surgery.
Constance P., a 64-year-old retired violin teacher, has been on prednisone 5 mg daily for rheumatoid arthritis for six years — a dose her rheumatologist has tried twice to taper further, each time backing off when her joint symptoms flared within weeks. She still teaches two private students a week from her living room, both of whom she has told, matter-of-factly, that surgery is coming and lessons will pause for a while, the same practical tone she uses to talk through a fingering problem. She is scheduled for a total hip arthroplasty next month, and her case sits at a genuinely awkward point in the perioperative literature: 5 mg is exactly the threshold one widely used classification treats as low enough that stress-dose steroids "are not required unless the patient exhibits signs of HPA axis suppression," while a separate, equally real 2020 UK anaesthesia society guideline defines any prednisolone-equivalent dose of 5 mg or more sustained for four weeks or longer as an adrenosuppressive dose warranting full perioperative stress coverage for major surgery. She is not on a borderline dose by accident of definition on one side or the other — she is on the literal line both frameworks are drawn at, with opposite conclusions.
Complicating the choice further, a genuinely published, non-fringe position exists questioning whether routine stress-dose supplementation is evidence-based at all: a systematic review by Marik and Varon, and a separate paper titled plainly "Perioperative glucocorticoid supplementation is not supported by evidence," both concluded that patients continuing their usual daily corticosteroid dose through surgery do not routinely need additional stress dosing on top of it. That position hasn't displaced the more cautious guidelines, but it is real literature, not a fringe outlier, and it means the team isn't choosing between an established standard and skepticism — it's choosing among three positions that have each been published as reasonable.
Pre-operative anesthesia evaluation, 4 weeks before surgery
Marik and Varon's systematic review, and the "not supported by evidence" paper that followed it, both found patients who continue their usual daily dose through surgery don't routinely need supplemental stress dosing on top of it. A total hip replacement carries a real infection risk, and unnecessary supraphysiologic steroid exposure works against wound healing and glucose control right when we want both working in her favor. I'd continue her usual 5mg and skip supplemental dosing.
I'd point to the other real guideline here — the 2020 UK anaesthesia society definition treats any prednisolone-equivalent dose of 5mg or more for four weeks or longer as adrenosuppressive, and recommends full stress coverage for major surgery. She's been on this exact dose for six years, and both times we've tried to come down even slightly, something gave — I don't think that's unrelated to how dependent her axis may be on this dose staying where it is.
I take the wound-healing concern seriously — I'm not dismissing it — I just think the actual guideline written for exactly her scenario, sustained adrenosuppressive dosing facing major surgery, shouldn't be set aside for a systematic review that hasn't displaced it.
We don't have to guess which guideline applies to her — we have four weeks before surgery, which is time enough for a cosyntropin stimulation test to answer the actual physiological question. If her axis responds normally, that supports the anesthesiologist's read; if it doesn't, that supports full coverage. Either way, we'd be basing the decision on her own HPA axis rather than on which published position we find more persuasive in the abstract.
Agreed: a cosyntropin stimulation test this week, with the final perioperative stress-dose plan built around the result rather than around either guideline alone.
Not agreed: what to do if the test result is itself borderline, neither clearly normal nor clearly suppressed. The rheumatologist would default to full coverage in that case, given her own taper history; the anesthesiologist would lean toward usual-dose-only given the systematic-review evidence and the real infection-risk tradeoff, if the test doesn't clearly resolve the question either way.